Magazine Article | August 1, 2023

Companies To Watch: Ventoux Biosciences

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases

SNAPSHOT
Ventoux Biosciences is an early-stage biopharma startup in preclinical development of medications for treating Dupuytren’s disease (palmar fibromatosis) and related fibrotic diseases. The company is developing two lead candidates, coded VEN-201 and VEN-202, for the same indications: Dupuytren’s, which causes painful deformities in the hand, and Ledderhose disease (plantar fibromatosis), which produces hard growths on the bottom of the foot.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: